Long noncoding RNA TP73-AS1 in human cancers

Feihu Chu; Lusha Xue; Haiyan Miao

doi:10.1016/j.cca.2019.09.024

Long noncoding RNA TP73-AS1 in human cancers

Clin Chim Acta. 2020 Jan:500:104-108. doi: 10.1016/j.cca.2019.09.024. Epub 2019 Oct 31.

Authors

Feihu Chu¹, Lusha Xue², Haiyan Miao³

Affiliations

¹ Department of Breast Surgery, Nantong Tumor Hospital, Nantong, China.
² Department of Urology, Nanjing Drum Tower Hospital, Nanjing, China.
³ Department of General Surgery, The Sixth People's Hospital of Nantong, Nantong, China; Nantong University, Nantong, China. Electronic address: miaohaiyan_0730@163.com.

PMID: 31678571
DOI: 10.1016/j.cca.2019.09.024

Abstract

Long noncoding RNAs (lncRNAs) play an important role in tumor development. With the development of sequencing technology, many new lncRNAs have been discovered. lncRNA TP73-AS1 is abnormally expressed in many cancers. A summary of the current literature related to TP73-AS1 reveals that TP73-AS1 mainly regulates the occurrence and development of tumors through the mechanism of competitive endogenous RNA (ceRNA). In addition, the abnormal expression of TP73-AS1 can regulate the malignant function of tumor cells through a variety of possible mechanisms. All evidence suggests that TP73-AS1 may be a potential diagnostic biomarker or a new cancer therapeutic target.

Keywords: Biomarker; Cancer; Long noncoding RNA; TP73-AS1; ceRNA.

Publication types

Review

MeSH terms

Humans
Neoplasms / genetics*
RNA, Long Noncoding / genetics*

Substances

RNA, Long Noncoding
long non-coding RNA KIAA0495, human